Key Points
- Teva EVP Eliyahu Sharon Kalif sold 153,251 shares on May 14 at an average price of $35.61, generating about $5.46 million. After the sale, he still held 172,184 shares, though his position was cut by 47.09%.
- Teva’s stock was trading modestly higher at $34.12, near its 52-week high of $37.35. The company also reported quarterly EPS of $0.53 on revenue of $3.98 billion.
- Analysts remain broadly positive on TEVA, with a consensus “Moderate Buy” rating and average target price of $41.78. Recent catalysts include a Fitch upgrade to investment grade and raised price targets from several major brokerages.
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Get Free Report) EVP Eliyahu Sharon Kalif sold 153,251 shares of the firm's stock in a transaction that occurred on Thursday, May 14th. The stock was sold at an average price of $35.61, for a total value of $5,457,268.11. Following the transaction, the executive vice president owned 172,184 shares in the company, valued at $6,131,472.24. This represents a 47.09% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Eliyahu Sharon Kalif also recently made the following trade(s):
- On Thursday, February 26th, Eliyahu Sharon Kalif sold 345,810 shares of Teva Pharmaceutical Industries stock. The stock was sold at an average price of $33.64, for a total value of $11,633,048.40.
Teva Pharmaceutical Industries Trading Up 0.3%
NYSE:TEVA opened at $34.12 on Wednesday. Teva Pharmaceutical Industries Ltd. has a 52-week low of $14.99 and a 52-week high of $37.35. The company has a quick ratio of 0.78, a current ratio of 1.01 and a debt-to-equity ratio of 1.70. The company has a market capitalization of $39.23 billion, a PE ratio of 25.65, a P/E/G ratio of 3.29 and a beta of 0.86. The stock's 50 day moving average price is $31.65 and its 200 day moving average price is $30.70.
Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last issued its quarterly earnings data on Tuesday, March 31st. The company reported $0.53 earnings per share (EPS) for the quarter. Teva Pharmaceutical Industries had a net margin of 9.01% and a return on equity of 43.53%. The company had revenue of $3.98 billion for the quarter. On average, research analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 2.49 EPS for the current year.
Key Stories Impacting Teva Pharmaceutical Industries
Here are the key news stories impacting Teva Pharmaceutical Industries this week:
Institutional Trading of Teva Pharmaceutical Industries
Several hedge funds and other institutional investors have recently made changes to their positions in TEVA. Aster Capital Management DIFC Ltd purchased a new stake in shares of Teva Pharmaceutical Industries in the fourth quarter valued at approximately $25,000. Cornerstone Planning Group LLC boosted its stake in shares of Teva Pharmaceutical Industries by 547.1% in the first quarter. Cornerstone Planning Group LLC now owns 893 shares of the company's stock valued at $27,000 after buying an additional 755 shares in the last quarter. Allworth Financial LP boosted its stake in shares of Teva Pharmaceutical Industries by 53.8% in the fourth quarter. Allworth Financial LP now owns 941 shares of the company's stock valued at $29,000 after buying an additional 329 shares in the last quarter. Grove Bank & Trust boosted its stake in shares of Teva Pharmaceutical Industries by 300.0% in the fourth quarter. Grove Bank & Trust now owns 1,000 shares of the company's stock valued at $31,000 after buying an additional 750 shares in the last quarter. Finally, EverSource Wealth Advisors LLC boosted its stake in shares of Teva Pharmaceutical Industries by 51.8% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,011 shares of the company's stock valued at $32,000 after buying an additional 345 shares in the last quarter. Hedge funds and other institutional investors own 54.05% of the company's stock.
Wall Street Analyst Weigh In
Several brokerages have weighed in on TEVA. The Goldman Sachs Group lifted their target price on Teva Pharmaceutical Industries from $36.00 to $45.00 and gave the company a "buy" rating in a research note on Monday, February 9th. JPMorgan Chase & Co. lifted their target price on Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the company an "overweight" rating in a research note on Thursday, April 30th. Piper Sandler reiterated an "overweight" rating and issued a $42.00 target price (up from $41.00) on shares of Teva Pharmaceutical Industries in a research note on Thursday, April 30th. UBS Group lifted their target price on Teva Pharmaceutical Industries from $36.00 to $42.00 and gave the company a "buy" rating in a research note on Thursday, April 30th. Finally, Wall Street Zen downgraded Teva Pharmaceutical Industries from a "strong-buy" rating to a "hold" rating in a research note on Saturday, May 2nd. Nine research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $41.78.
Read Our Latest Research Report on TEVA
Teva Pharmaceutical Industries Company Profile
(
Get Free Report)
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world's largest manufacturers of generic medicines. The company's core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.
Teva's product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
